In hematologic malignancies, CD19/CD22 TanCARs have demonstrated preclinical efficacy against B-ALL, and a clinical study in 2020 evaluating CD19/CD20 TanCARs in refractory or relapsed B-cell lymphoma reported a 79% overall response rate, 71% complete response rate, and 64% progression-free survival rate [57–60]. The gene discussed is CD19; the disease is B-cell non-Hodgkin lymphoma.